Therapy Areas: Vaccines
Norway to discontinue AstraZeneca COVID-19 vaccine use
12 May 2021 -

Norway will not resume its use of the COVID-19 vaccine made by British pharmaceutical company AstraZeneca Inc (LON:AZN) due to a risk of rare but harmful side-effects, Reuters news agency reported on Wednesday, quoting the VG newspaper.

The Prime Minister of Norway, Erna Solberg, is expected to announce at 16:00 hours GMT on 12 May 2021 whether Norway will resume the use of the AstraZeneca shot, as well as the government's decision on Johnson & Johnson's vaccine.

Reportedly, Norwegian authorities on 11 March 2021 suspended the AstraZeneca rollout after a small number of younger inoculated people were hospitalised for a combination of blood clots, bleeding and a low count of platelets, some of whom later died.

A study in Denmark and Norway found slightly increased rates of vein blood clots among people who have had a first dose of AstraZeneca's vaccine, including clots in the brain, compared with expected rates in the general population.

On 10 May 2021, a public panel of medical, legal and other experts said the two COVID-19 vaccines should not be offered as part of Norway's inoculation scheme, although volunteers should be allowed to take them.